Pharmaceutical Research Transparency Act of 2022

Summary

Pharmaceutical Research Transparency Act of 2022 This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development. Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion. The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 7 April 2022

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 7 April 2022

   Introduced

   Introduced in House

   Source: IntroReferral

3. 7 April 2022

   Introduced

   Introduced in House

   Source: IntroReferral

4. 8 April 2022

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 7 April 2022 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 7 April 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 7 April 2022

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 7 April 2022

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Maloney, Carolyn B. [D-NY-12] · D · Sponsor
• Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
• Sen. Welch, Peter [D-VT] · D · Sponsor
• Rep. Porter, Katie [D-CA-47] · D · Sponsor
• Rep. DeSaulnier, Mark [D-CA-10] · D · Sponsor
• Rep. Raskin, Jamie [D-MD-8] · D · Sponsor
• Rep. Kuster, Ann M. [D-NH-2] · D · Cosponsor
• Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Cosponsor
• Rep. Grijalva, Raúl M. [D-AZ-7] · D · Cosponsor
• Rep. Scanlon, Mary Gay [D-PA-5] · D · Cosponsor
• Rep. Takano, Mark [D-CA-39] · D · Cosponsor
• Rep. DeFazio, Peter A. [D-OR-4] · D · Cosponsor
• Rep. Chu, Judy [D-CA-28] · D · Cosponsor
• Rep. Barragán, Nanette Diaz [D-CA-44] · D · Cosponsor
• Rep. Pocan, Mark [D-WI-2] · D · Cosponsor
• Rep. Jayapal, Pramila [D-WA-7] · D · Cosponsor
• · hsif00 · Standing
• · hsba00 · Standing

Related records

• related to → Pharmaceutical Research Transparency Act of 2022